Evidence map›Paper›PMID 41279907›Full record

ArticlebioRxiv : the preprint server for biology2025

Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines.

Rafiq Ahmad Khan, Junjian Chen, Luke Donius, Ellis L Reinherz, Mikyung Kim

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Rafiq Ahmad Khan
Junjian Chen
Luke Donius
Ellis L Reinherz
Mikyung Kim

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subdominant B-cell immune responses to conserved epitopes are major obstacles in eliciting broadly neutralizing antibodies (bnAbs) against HIV-1 through natural infection or vaccination. Although the sequence conserved membrane proximal external domain (MPER) of HIV-1 gp41 is partially occluded on the virion surface, epitope-focused immunogens could mitigate access limitations. Here, we found that a MPER/liposome vaccine delivered with single CD4 T cell helper epitope results in a post-priming response hierarchy, eliciting low affinity MPER-specific B cells. Heterologous boosting, however, promotes MPER-specific B cell clonal expansion and enhances plasma antibody functionality. This improvement is associated with increased B cell affinity for MPER and reduced competition from B cells targeting the helper epitope. While helper peptide co-delivery increases affinity of serum antibodies, the outcome of subsequent MPER antibody responses is shaped by the priming antigen. Our results offer insights into heterologous immunization strategies to potentiate subdominant B cell responses against frequently mutating viruses. Significance Statement: A key challenge in vaccination against mutable viruses like HIV-1 is the immune system's focus on highly variable regions. The conserved MPER segment of gp41 elicits weak antibody responses due to poor B cell accessibility. This study evaluated a liposome-based MPER vaccine strategy. Initial priming generated low-affinity MPER-specific memory B cells, influenced by strong B cell affinity for a dominant T cell helper peptide. However, heterologous boosting overcomes subdominant MPER responses by increasing B cell affinity for booster immunogens while also reducing competition from other helper peptides. Co-delivery of helper peptides enhanced antibody affinity, though the priming antigen was critical in shaping responses. These findings suggest heterologous immunization is a promising strategy to enhance subdominant B cell responses.

Identifiers

PMID41279907
PMCPMC12633018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.